Skip to main
TOI

TOI Stock Forecast & Price Target

TOI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

The Oncology Institute Inc. is poised for financial growth due to its strategic partnership with Helios, which is expected to enhance margins significantly by 2026 and 2027, and align with an overall trend towards an expansion of margins back to the 12%-15% range as contracts mature. Growth potential in its fee-for-service (FFS) segment is supported by an increasing oncology market and new market penetrations, with robust dispensing revenue anticipated, particularly following the opening of a new pharmacy in California that adheres to state regulations. Additionally, the transition towards value-based care arrangements provides a pathway for higher incremental margins, while the elimination of the DIR fee has improved expense visibility, contributing to a rebound in margins expected in 2025.

Bears say

The Oncology Institute Inc. has faced significant challenges in its financial performance, primarily due to contract losses in 2024 that adversely affected gross margins, along with a lack of aggressive growth projections compared to industry trends. Additionally, the company experienced a detrimental impact on dispensary margins attributed to the elimination of DIR fees, resulting in a $15 million headwind for this segment. Market pressures such as increased drug prices and the financial health of payer partnerships further threaten the company's ability to achieve sustainable profitability, as indicated by the expectation of only reaching break-even EBITDA by late 2025.

TOI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Oncology Institute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Oncology Institute (TOI) Forecast

Analysts have given TOI a Strong Buy based on their latest research and market trends.

According to 3 analysts, TOI has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Oncology Institute (TOI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.